patent/CN-104640860-A

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate	2013-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83a7246c161cc7884bc28742c67e3807 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c62c05f1a8315de558c98752864cfdb
publicationDate	2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-104640860-A
titleOfInvention	Azaindoline
abstract	The application discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein W, Y, Z, R 1 , R 2 , R 3 and R 4 are as described in the application, and discloses the use of the compound Methods of treating cancer.
priorityDate	2012-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012106343-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010190688-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012157390-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102171209-A
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466818408

Total number of triples: 22.